BI 1002494, a Novel Potent and Selective Oral Spleen Tyrosine Kinase Inhibitor, Displays Differential Potency in Human Basophils and B Cells.
Lamb DJ, Wollin SL, Schnapp A, Bischoff D, Erb KJ, Bouyssou T, Guilliard B, Strasser C, Wex E, Blum S, Thaler E, Nickel H, Radmacher O, Haas H, Swantek JL, Souza D, Canfield M, White D, Panzenbeck M, Kashem MA, Sanville-Ross M, Kono T, Sewald K, Braun A, Obernolte H, Danov O, Schaenzle G, Rast G, Maier GM, Hoffmann M.
Lamb DJ, et al. Among authors: obernolte h.
J Pharmacol Exp Ther. 2016 Jun;357(3):554-61. doi: 10.1124/jpet.116.233155. Epub 2016 Apr 5.
J Pharmacol Exp Ther. 2016.
PMID: 27048659